KRAS and cancer: We recently reported that the ectopic expression of the chemically modified MIR143-3p#12 (CM-MIR143#12) induces significant inhibition of cancer cell growth through the targeting of KRAS, AKT, and ERK in colorectal [35], bladder [36], and gastric cancer cells [37].